JP2015527398A - 聴覚喪失治療 - Google Patents

聴覚喪失治療 Download PDF

Info

Publication number
JP2015527398A
JP2015527398A JP2015531223A JP2015531223A JP2015527398A JP 2015527398 A JP2015527398 A JP 2015527398A JP 2015531223 A JP2015531223 A JP 2015531223A JP 2015531223 A JP2015531223 A JP 2015531223A JP 2015527398 A JP2015527398 A JP 2015527398A
Authority
JP
Japan
Prior art keywords
cells
years old
hair
methyl
hearing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015531223A
Other languages
English (en)
Japanese (ja)
Inventor
エッジ，アルバート
岡野　栄之
栄之 岡野
正人 藤岡
正人 藤岡
邦雄 水足
邦雄 水足
Original Assignee
マサチューセッツ アイ アンド イヤー インファーマリー
マサチューセッツ アイ アンド イヤー インファーマリー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マサチューセッツ アイ アンド イヤー インファーマリー, マサチューセッツ アイ アンド イヤー インファーマリー filed Critical マサチューセッツ アイ アンド イヤー インファーマリー
Publication of JP2015527398A publication Critical patent/JP2015527398A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2015531223A 2012-09-07 2013-09-06 聴覚喪失治療 Withdrawn JP2015527398A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698475P 2012-09-07 2012-09-07
US61/698,475 2012-09-07
PCT/US2013/058446 WO2014039781A1 (en) 2012-09-07 2013-09-06 Treating hearing loss

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019091552A Division JP2019172679A (ja) 2012-09-07 2019-05-14 聴覚喪失治療

Publications (1)

Publication Number Publication Date
JP2015527398A true JP2015527398A (ja) 2015-09-17

Family

ID=50237627

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015531223A Withdrawn JP2015527398A (ja) 2012-09-07 2013-09-06 聴覚喪失治療
JP2019091552A Withdrawn JP2019172679A (ja) 2012-09-07 2019-05-14 聴覚喪失治療
JP2020180340A Withdrawn JP2021038228A (ja) 2012-09-07 2020-10-28 聴覚喪失治療
JP2022069599A Pending JP2022109965A (ja) 2012-09-07 2022-04-20 聴覚喪失治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019091552A Withdrawn JP2019172679A (ja) 2012-09-07 2019-05-14 聴覚喪失治療
JP2020180340A Withdrawn JP2021038228A (ja) 2012-09-07 2020-10-28 聴覚喪失治療
JP2022069599A Pending JP2022109965A (ja) 2012-09-07 2022-04-20 聴覚喪失治療

Country Status (7)

Country Link
US (3) US20150209367A1 (enExample)
EP (2) EP2892506B1 (enExample)
JP (4) JP2015527398A (enExample)
AU (1) AU2013312358B2 (enExample)
CA (1) CA2883896C (enExample)
HK (1) HK1211875A1 (enExample)
WO (1) WO2014039781A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532798A (ja) * 2015-10-30 2018-11-08 インセプション ３， インコーポレイテッド 耳の疾患および障害の処置におけるジベンゾアゼピン化合物およびその使用
JP2020503380A (ja) * 2016-12-16 2020-01-30 パイプライン セラピューティクス， インコーポレイテッド 蝸牛シナプス障害を処置する方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007334260A1 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
WO2014039781A1 (en) * 2012-09-07 2014-03-13 Massachusetts Eye & Ear Infirmary Treating hearing loss
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
EP3368553B1 (en) * 2015-10-27 2023-08-02 Purdue Research Foundation Polymer-based therapeutics for inductive browning of fat
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
WO2017132530A1 (en) 2016-01-29 2017-08-03 Massachusetts Eye And Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
CN109689027A (zh) 2016-06-29 2019-04-26 奥德纳米有限公司 甘油三酯耳用制剂及其用途
US10576125B2 (en) 2016-10-31 2020-03-03 Hough Ear Institute Methods for enhancing synaptogenesis and neuritogenesis
US20220192984A1 (en) 2018-10-02 2022-06-23 Frequency Therapeutics, Inc. Pharmaceutical compositions comprising otic therapeutic agents and related methods
KR20220007050A (ko) 2019-04-08 2022-01-18 프리퀀시 테라퓨틱스, 인크. 난청을 치료하기 위한 chir99021과 발프로산의 조합
TWI781536B (zh) 2021-02-26 2022-10-21 國立臺灣科技大學 藥物釋放組合物、其製造方法及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006117536A (ja) * 2004-10-19 2006-05-11 Kyoto Univ 内耳の有毛細胞を誘導するための医薬
JP2012509899A (ja) * 2008-11-24 2012-04-26 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞を産生するための経路

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
USD309535S (en) 1987-03-30 1990-07-31 Chromcraft Furniture Corp. Chair
USD360535S (en) 1994-02-14 1995-07-25 Staffan Sjoberg Combined beach chair and beach mattress
PT951466E (pt) 1996-12-23 2009-04-09 Lilly Co Eli Compostos cicloalquilo, lactama, lactona e relacionados, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da libertação do péptido β-amilóide e/ou da sua síntese pela utilização de tais compostos
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6683048B1 (en) 1997-04-10 2004-01-27 Mcgill University Compounds and methods for stimulating gene expression and cellular differentiation
ATE274510T1 (de) 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
WO2000059939A1 (en) 1999-04-05 2000-10-12 Adherex Technologies Inc. COMPOUNDS AND METHODS FOR STIMULATING β-CATENIN MEDIATED GENE EXPRESSION AND DIFFERENTIATION
ATE384704T1 (de) 1999-12-17 2008-02-15 Novartis Vaccines & Diagnostic Pyrazin-basierte hemmer der glycogen-synthase- kinase 3
EP1254108A1 (en) 2000-01-24 2002-11-06 MERCK SHARP & DOHME LTD. Gamma-secretase inhibitors
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
ES2275657T3 (es) 2000-03-20 2007-06-16 MERCK SHARP & DOHME LTD. Derivados de bicicloalquilo puenteados sulfonamido sustituidos.
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
USD447031S1 (en) 2000-04-20 2001-08-28 Wang Keaun Oh Hand carry air tacker
AU2001288219C1 (en) 2000-07-11 2009-12-03 Sound Pharmaceuticals Incorporated Stimulation of cellular regeneration and differentiation in the inner ear
US7399633B2 (en) 2000-10-27 2008-07-15 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
WO2002036555A1 (en) 2000-11-02 2002-05-10 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
US6483732B2 (en) 2000-12-13 2002-11-19 Koninklijke Philips Electronics N.V. Relational content addressable memory
GB0119152D0 (en) 2001-08-06 2001-09-26 Merck Sharp & Dohme Therapeutic agents
US7206639B2 (en) 2002-03-15 2007-04-17 Sarcos Investments Lc Cochlear drug delivery system and method
GB0209991D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
DE60328182D1 (de) 2002-05-01 2009-08-13 Merck Sharp & Dohme Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
GB0209995D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209997D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0225475D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0225474D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
AU2004221881A1 (en) 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
CL2004000647A1 (es) 2003-03-31 2005-02-04 Wyeth Corp Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
WO2005010524A1 (en) 2003-06-04 2005-02-03 Curis, Inc. Stem cell-based methods for identifying and characterizing agents
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
AU2004268647B2 (en) 2003-08-28 2010-07-01 Choongwae Pharma Corporation Modulation of beta-catenin/TCF activated transcription
EP1667984B1 (en) 2003-09-24 2011-05-18 Merck Sharp & Dohme Ltd. Gamma-secretase inhibitors
GB0326039D0 (en) 2003-11-07 2003-12-10 Merck Sharp & Dohme Therapeutic agents
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
BRPI0507168A (pt) 2004-01-27 2007-06-26 Nuvelo Inc fator proliferativo gastrointestinal e aplicações do mesmo
WO2005072793A1 (en) 2004-01-29 2005-08-11 The Charles Stark Draper Laboratory, Inc. Implantable drug delivery apparatus
UA93181C2 (ru) 2004-02-23 2011-01-25 Эли Лилли Энд Компани СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ
WO2007030743A2 (en) 2005-09-08 2007-03-15 Massachusetts Eye & Ear Infirmary Cochlear implants containing biological cells and uses thereof
US20090306045A1 (en) 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
WO2007100895A2 (en) 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
US8158364B2 (en) * 2006-04-11 2012-04-17 The Board Of Regents Of The University Of Texas System Methods and compositions involving nucleotide repeat disorders
US8175269B2 (en) 2006-07-05 2012-05-08 Oracle International Corporation System and method for enterprise security including symmetric key protection
AU2007334260A1 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
WO2008071605A2 (en) 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
KR101136260B1 (ko) 2007-08-14 2012-04-19 일라이 릴리 앤드 캄파니 감마-세크레타제 억제제로서의 아제핀 유도체
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
KR20140007979A (ko) 2008-01-11 2014-01-20 에프. 호프만-라 로슈 아게 암 치료를 위한 감마-세크레타제 저해제의 용도
CN101990433B (zh) 2008-02-07 2014-11-05 马萨诸塞眼科耳科诊所 提高Atoh1表达的化合物
KR20160029870A (ko) 2008-04-21 2016-03-15 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
GB2459910B (en) 2008-04-21 2010-03-31 Otonomy Inc Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders
CN103417472B (zh) 2008-05-14 2018-01-02 奥德纳米有限公司 用于治疗耳部病症的控制释放皮质类固醇组合物和方法
US8648119B2 (en) * 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2010068564A1 (en) 2008-12-11 2010-06-17 Merck Sharp & Dohme Corp. Method for treating alzheimer's disease and related conditions
EP2393776B1 (en) 2009-02-06 2014-05-14 Merck Sharp & Dohme Corp. Novel trifluoromethylsulfonamide gamma secretase inhibitor
CN102686580B (zh) 2009-10-28 2014-09-10 美国辉瑞有限公司 用作酪蛋白激酶抑制剂的咪唑衍生物
CA134865S (en) 2010-02-11 2010-11-10 Hankook Tire Co Ltd Automobile tire
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
CN102947451B (zh) 2010-05-26 2017-09-22 库尔纳公司 通过抑制无调同源物1(atoh1)的天然反义转录物而治疗atoh1相关疾病
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
RU2456356C1 (ru) 2011-04-29 2012-07-20 Борис Сергеевич Кустов Коллоидный раствор наносеребра и способ его получения
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
WO2014039781A1 (en) * 2012-09-07 2014-03-13 Massachusetts Eye & Ear Infirmary Treating hearing loss
PT3702443T (pt) 2013-03-14 2022-02-17 Massachusetts Inst Technology Composições e métodos para expansão e cultura de células estaminais epiteliais
WO2014145205A2 (en) 2013-03-15 2014-09-18 St. Jude Children's Research Hospital Methods and compositions of p27kip1 transcription modulators
US10603295B2 (en) 2014-04-28 2020-03-31 Massachusetts Eye And Ear Infirmary Sensorineural hair cell differentiation
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
JO3491B1 (ar) 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
WO2017120543A1 (en) 2016-01-08 2017-07-13 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
WO2017132530A1 (en) 2016-01-29 2017-08-03 Massachusetts Eye And Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
AU2017376109A1 (en) 2016-12-16 2019-07-11 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
WO2020112883A1 (en) 2018-11-30 2020-06-04 Massachusetts Eye And Ear Infirmary Inhibition of lysine demethylase 1 (lsd1) induces differentiation of hair cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006117536A (ja) * 2004-10-19 2006-05-11 Kyoto Univ 内耳の有毛細胞を誘導するための医薬
JP2012509899A (ja) * 2008-11-24 2012-04-26 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞を産生するための経路

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AUDIOLOGICAL MEDICINE, 2005, VOL.3 NO.2, P.82-89, JPN6018022091, ISSN: 0003817243 *
NEUROREPORT., 2007, VOL.18 NO.18, P.1911-1914, JPN6018022089, ISSN: 0004117548 *
NEUROSCI RES., 2008, VOL.61 SUPPL 1., P.S25(ABSTRACT NUMBER SY3A-H5), JPN6019036243, ISSN: 0004117549 *
OTOL JPN, vol. Vol. 18(4), JPN6017025425, 2008, pages 275, ISSN: 0003954159 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532798A (ja) * 2015-10-30 2018-11-08 インセプション ３， インコーポレイテッド 耳の疾患および障害の処置におけるジベンゾアゼピン化合物およびその使用
JP2020503380A (ja) * 2016-12-16 2020-01-30 パイプライン セラピューティクス， インコーポレイテッド 蝸牛シナプス障害を処置する方法

Also Published As

Publication number Publication date
US20210299138A1 (en) 2021-09-30
US20150209367A1 (en) 2015-07-30
JP2022109965A (ja) 2022-07-28
CA2883896A1 (en) 2014-03-13
HK1211875A1 (en) 2016-06-03
US12161647B2 (en) 2024-12-10
EP3970725A1 (en) 2022-03-23
CA2883896C (en) 2023-03-07
US20180369253A1 (en) 2018-12-27
US10898492B2 (en) 2021-01-26
EP3970725B1 (en) 2025-08-20
EP2892506A4 (en) 2016-04-20
EP2892506A1 (en) 2015-07-15
AU2013312358B2 (en) 2018-08-09
EP2892506B1 (en) 2021-11-03
JP2019172679A (ja) 2019-10-10
WO2014039781A1 (en) 2014-03-13
JP2021038228A (ja) 2021-03-11
AU2013312358A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
US12161647B2 (en) Treating hearing loss
US12427128B2 (en) Sensorineural hair cell differentiation
JP6773645B2 (ja) 聴覚障害の治療のための内耳毛細胞を生成するための組成物、システムおよび方法
CA2884309A1 (en) Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
US12419876B2 (en) Treatment of hearing loss by inhibition of casein kinase 1
Berkowski et al. Assessment of topical therapies for improving the optical clarity following stromal wounding in a novel ex vivo canine cornea model
US20220008433A1 (en) Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells
JP5066444B2 (ja) 聴力損失を予防及び／又は治療するためのフェノチアジン誘導体の使用
US20240100079A1 (en) Methods and compositions for regenerating hair cells in the inner ear of adult mammals
CA3109647A1 (en) Compositions and methods for generating hair cells by upregulating jag-1
EP3837350A1 (en) Compositions and methods for generating hair cells by upregulating pi3k
US20240382461A1 (en) Pharmaceutical composition and method for prevention and treatment of hearing loss

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180918

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190514

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190514

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190528

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190709

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190716

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190920

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20191001

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200407

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200619

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201020

C27C Written answer of applicant after an oral proceeding

Free format text: JAPANESE INTERMEDIATE CODE: C2721

Effective date: 20201020

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210105

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20210408